nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—ABCG2—Dactinomycin—ocular cancer	0.493	0.598	CbGbCtD
Leflunomide—ABCG2—Carboplatin—ocular cancer	0.331	0.402	CbGbCtD
Leflunomide—AHR—Adipogenesis—E2F4—ocular cancer	0.00546	0.0311	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—RBL1—ocular cancer	0.00535	0.0305	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—RBL2—ocular cancer	0.00492	0.028	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.00474	0.027	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—CRTC1—ocular cancer	0.00473	0.0269	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—ID2—ocular cancer	0.00421	0.024	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.00408	0.0233	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CCND3—ocular cancer	0.00393	0.0224	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CDC25A—ocular cancer	0.00392	0.0223	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—CCND2—ocular cancer	0.0034	0.0194	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—CRTC1—ocular cancer	0.00339	0.0193	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.00336	0.0191	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—GNA11—ocular cancer	0.00293	0.0167	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CDK6—ocular cancer	0.00293	0.0167	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—GNA11—ocular cancer	0.00289	0.0165	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—HDAC1—ocular cancer	0.00282	0.0161	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—GNAQ—ocular cancer	0.00273	0.0155	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—GNAQ—ocular cancer	0.00269	0.0153	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—ID2—ocular cancer	0.00262	0.0149	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ocular cancer	0.00261	0.0149	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.00261	0.0149	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—MYBL2—ocular cancer	0.00251	0.0143	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.00241	0.0137	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—CDKN1B—ocular cancer	0.00234	0.0133	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EP300—ocular cancer	0.00229	0.0131	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.00229	0.0131	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—CCND1—ocular cancer	0.00223	0.0127	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—HDAC1—ocular cancer	0.00222	0.0127	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CCND3—ocular cancer	0.00218	0.0124	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—GNA11—ocular cancer	0.00211	0.012	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—E2F1—ocular cancer	0.00206	0.0117	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—PSPH—ocular cancer	0.00205	0.0117	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.002	0.0114	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TGFB1—ocular cancer	0.00199	0.0114	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—CDK2—ocular cancer	0.00197	0.0112	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—GNAQ—ocular cancer	0.00196	0.0112	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—E2F1—ocular cancer	0.00183	0.0104	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—MYC—ocular cancer	0.00179	0.0102	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—HDAC1—ocular cancer	0.00177	0.0101	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CDK2—ocular cancer	0.0017	0.00968	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—ocular cancer	0.00162	0.00925	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CDK2—ocular cancer	0.00158	0.00899	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	0.00157	0.00894	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CDK4—ocular cancer	0.00149	0.0085	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—RB1—ocular cancer	0.00146	0.00833	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—RB1—ocular cancer	0.0013	0.00739	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1B—ocular cancer	0.00128	0.00729	CbGpPWpGaD
Leflunomide—PTK2B—IL-7 Signaling Pathway—AKT1—ocular cancer	0.00124	0.00706	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—CDK4—ocular cancer	0.00119	0.00676	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1A—ocular cancer	0.00118	0.00673	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—MYC—ocular cancer	0.00118	0.00672	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—CDKN1B—ocular cancer	0.00112	0.00635	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MDM2—ocular cancer	0.00111	0.0063	CbGpPWpGaD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—HRAS—ocular cancer	0.0011	0.00625	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—CCND1—ocular cancer	0.00109	0.00622	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—CDKN1B—ocular cancer	0.00109	0.0062	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—CDKN1A—ocular cancer	0.00105	0.00598	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—MYC—ocular cancer	0.000965	0.0055	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—CCND1—ocular cancer	0.000963	0.00549	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—E2F1—ocular cancer	0.000949	0.00541	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—HRAS—ocular cancer	0.000927	0.00528	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EP300—ocular cancer	0.000887	0.00505	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—TGFB1—ocular cancer	0.000869	0.00495	CbGpPWpGaD
Leflunomide—PTK2B—Interleukin-2 signaling—HRAS—ocular cancer	0.000847	0.00483	CbGpPWpGaD
Leflunomide—PTK2B—IL-2 Signaling Pathway—AKT1—ocular cancer	0.000819	0.00466	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—MYC—ocular cancer	0.000773	0.0044	CbGpPWpGaD
Leflunomide—PTK2B—IL2-mediated signaling events—HRAS—ocular cancer	0.000758	0.00432	CbGpPWpGaD
Leflunomide—ABCG2—HIF-2-alpha transcription factor network—EP300—ocular cancer	0.000746	0.00425	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—EP300—ocular cancer	0.000705	0.00402	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—TP53—ocular cancer	0.000684	0.00389	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—ocular cancer	0.00068	0.00387	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—HRAS—ocular cancer	0.00067	0.00382	CbGpPWpGaD
Leflunomide—PTK2B—FGF signaling pathway—AKT1—ocular cancer	0.00067	0.00381	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—HRAS—ocular cancer	0.000662	0.00377	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—HRAS—ocular cancer	0.000654	0.00372	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GNA11—ocular cancer	0.000645	0.00367	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—TGFB1—ocular cancer	0.00064	0.00365	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—TP53—ocular cancer	0.000635	0.00361	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—ocular cancer	0.000634	0.00361	CbGpPWpGaD
Leflunomide—PTK2B—Coregulation of Androgen receptor activity—AKT1—ocular cancer	0.000607	0.00346	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GNAQ—ocular cancer	0.0006	0.00342	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—AKT1—ocular cancer	0.000592	0.00337	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—AKT1—ocular cancer	0.000592	0.00337	CbGpPWpGaD
Leflunomide—PTK2B—LPA receptor mediated events—AKT1—ocular cancer	0.000584	0.00333	CbGpPWpGaD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—AKT1—ocular cancer	0.000577	0.00329	CbGpPWpGaD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—ocular cancer	0.000557	0.00317	CbGpPWpGaD
Leflunomide—ABCG2—Fluoropyrimidine Activity—TP53—ocular cancer	0.000547	0.00311	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—AKT1—ocular cancer	0.000536	0.00305	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—E2F1—ocular cancer	0.000522	0.00297	CbGpPWpGaD
Leflunomide—AHR—Circadian rythm related genes—TP53—ocular cancer	0.000505	0.00287	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—HRAS—ocular cancer	0.000504	0.00287	CbGpPWpGaD
Leflunomide—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—ocular cancer	0.000485	0.00276	CbGpPWpGaD
Leflunomide—PTK2B—CXCR4-mediated signaling events—AKT1—ocular cancer	0.00047	0.00268	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDK2—ocular cancer	0.00045	0.00256	CbGpPWpGaD
Leflunomide—PTK2B—TCR Signaling Pathway—AKT1—ocular cancer	0.000445	0.00253	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—HRAS—ocular cancer	0.000439	0.0025	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—EP300—ocular cancer	0.000439	0.0025	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—HRAS—ocular cancer	0.000436	0.00248	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—HRAS—ocular cancer	0.000414	0.00236	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—SAG—ocular cancer	0.000395	0.00225	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—AKT1—ocular cancer	0.000387	0.00221	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RB1—ocular cancer	0.00037	0.00211	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—AKT1—ocular cancer	0.000366	0.00208	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—E2F5—ocular cancer	0.00035	0.00199	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—HRAS—ocular cancer	0.000346	0.00197	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—E2F4—ocular cancer	0.000343	0.00195	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RBL1—ocular cancer	0.000336	0.00191	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—PSPH—ocular cancer	0.000332	0.00189	CbGpPWpGaD
Leflunomide—CYP1A2—Tryptophan metabolism—MDM2—ocular cancer	0.000315	0.0018	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—HRAS—ocular cancer	0.000315	0.00179	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—AKT1—ocular cancer	0.000305	0.00174	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—E2F3—ocular cancer	0.000291	0.00166	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ocular cancer	0.000288	0.00164	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—ocular cancer	0.000288	0.00164	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—AKT1—ocular cancer	0.000278	0.00158	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TFDP1—ocular cancer	0.000271	0.00154	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—ocular cancer	0.000266	0.00151	CbGpPWpGaD
Leflunomide—ABCG2—HIF-1-alpha transcription factor network—AKT1—ocular cancer	0.000265	0.00151	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—ocular cancer	0.000253	0.00144	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EP300—ocular cancer	0.000253	0.00144	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—ocular cancer	0.00022	0.00125	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—ocular cancer	0.00022	0.00125	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—EP300—ocular cancer	0.000216	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MAML2—ocular cancer	0.000215	0.00123	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—HRAS—ocular cancer	0.000203	0.00116	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GNA11—ocular cancer	0.000188	0.00107	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—GNAQ—ocular cancer	0.000175	0.000994	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—ocular cancer	0.000173	0.000985	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—PSPH—ocular cancer	0.000167	0.000954	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HDAC1—ocular cancer	0.000157	0.000896	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—PSPH—ocular cancer	0.000143	0.000815	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN2B—ocular cancer	0.000141	0.000803	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AKT1—ocular cancer	0.00013	0.000742	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—E2F1—ocular cancer	0.000129	0.000737	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—MDM2—ocular cancer	0.000121	0.000689	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1B—ocular cancer	0.00011	0.000629	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNA11—ocular cancer	0.000104	0.000594	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CDKN1A—ocular cancer	0.000102	0.000581	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GNAQ—ocular cancer	9.7e-05	0.000553	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EP300—ocular cancer	9.7e-05	0.000552	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MDM2—ocular cancer	7.82e-05	0.000445	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1B—ocular cancer	7.14e-05	0.000407	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CCND1—ocular cancer	6.81e-05	0.000388	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—HRAS—ocular cancer	6.64e-05	0.000378	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CDKN1A—ocular cancer	6.59e-05	0.000375	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EP300—ocular cancer	6.27e-05	0.000357	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—AKT1—ocular cancer	5.86e-05	0.000334	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—MYC—ocular cancer	5.46e-05	0.000311	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TGFB1—ocular cancer	5.45e-05	0.00031	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNA11—ocular cancer	5.27e-05	0.0003	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GNAQ—ocular cancer	4.9e-05	0.000279	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNA11—ocular cancer	4.5e-05	0.000257	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—TP53—ocular cancer	4.49e-05	0.000256	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—HRAS—ocular cancer	4.29e-05	0.000244	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GNAQ—ocular cancer	4.19e-05	0.000238	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—ocular cancer	3.95e-05	0.000225	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AKT1—ocular cancer	3.79e-05	0.000216	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—EP300—ocular cancer	3.49e-05	0.000199	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—EP300—ocular cancer	3.38e-05	0.000192	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AKT1—ocular cancer	2.11e-05	0.00012	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—EP300—ocular cancer	1.76e-05	0.0001	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—EP300—ocular cancer	1.5e-05	8.57e-05	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AKT1—ocular cancer	1.06e-05	6.06e-05	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AKT1—ocular cancer	9.09e-06	5.18e-05	CbGpPWpGaD
